焦虑障碍疾病风险与心理治疗反应的表观遗传标记:DNA甲基化组的纵向分析
在迄今最大的焦虑障碍纵向样本(415例接受暴露认知行为治疗的患者与315名健康对照)中,于基线、治疗后及6个月随访进行全表观基因组关联研究,发现焦虑障碍与148个CpG位点DNA甲基化改变显著相关,部分位点提示与治疗反应及CBT应答中的动态甲基化变化相关。
要点
- 焦虑障碍与148个CpG位点甲基化改变显著相关(p≤6.409E-08),独立于抑郁共病。
- 基线7个和3个CpG位点分别提示与治疗后及随访时治疗反应相关(p<1E-5)。
- 4个CpG位点从基线至随访提示与CBT应答相关的动态甲基化变化。
核心结论
- 焦虑障碍与部分映射至焦虑、脑疾病、学习或可塑性相关基因的DNA甲基化改变显著相关。
- 部分CpG位点甲基化提示与暴露认知行为治疗反应及治疗中的动态变化相关。
- 表观遗传生物标志物可能有助于开发基于环境的预防策略及更靶向的个体化治疗。
研究设计与样本
- 在迄今最大的焦虑障碍纵向样本中开展全表观基因组关联研究(EWAS)。
- 样本为415例接受暴露认知行为治疗(CBT)的焦虑障碍患者和315名健康对照。
- 在基线、治疗后和6个月随访三个时间点进行DNA甲基化检测(Illumina MethylationEPIC BeadChip)。
- 经过预处理和质量控制后,分析样本为378例患者与295名对照。
主要发现
- 焦虑障碍与148个CpG位点DNA甲基化改变显著相关(p≤6.409E-08),独立于抑郁共病。
- 148个CpG位点部分映射至GABBR2、GABRD、GAST、IL12RB2、LINC00293、LOC101928626、MFGE8、NOTCH4、PTPRN2、RIMBP2、SPTBN1等基因及近期跨焦虑障碍EWAS中的TAOK1。
- 基线DNA甲基化在7个CpG位点(ABCA7、ADRA2C、LTBR、RPSAP52、SH3RF3、SLC47A2、ZNF251)提示与治疗后治疗反应相关(p<1E-5)。
- 基线DNA甲基化在3个CpG位点(ADGRD1、PRSS58、USP47)提示与随访时治疗反应相关(p<1E-5)。
- 4个CpG位点(ADIPOR2、EIF3B、OCA2、TMCC1)从基线至随访提示与CBT应答相关的动态全表观基因组DNA甲基化变化。
关键数值与推荐
- 焦虑障碍与DNA甲基化改变的关联显著性阈值为p≤6.409E-08。
- 治疗反应相关分析中提示性关联的阈值为p<1E-5。
- 经过预处理和质量控制后,分析样本为378例患者与295名对照。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Epigenetic mechanisms such as DNA methylation are hypothesized to play a pivotal role in the pathogenesis of anxiety disorders and to predict as well as relate to treatment response. An epigenome-wide association study (EWAS) (Illumina MethylationEPIC BeadChip) was performed at baseline (BL), post-treatment (POST) and 6-month follow-up (FU) in the so far largest longitudinal sample of patients with anxiety disorders (N = 415) treated with exposure-based cognitive behavioral therapy (CBT), and in 315 healthy controls. Independent of comorbidity with depression, anxiety disorders were significantly (p ≤ 6.409E-08) associated with altered DNA methylation at 148 CpGs partly mapping to genes previously implicated in processes related to anxiety, brain disorders, learning or plasticity (e.g., GABBR2, GABRD, GAST, IL12RB2, LINC00293, LOC101928626, MFGE8, NOTCH4, PTPRN2, RIMBP2, SPTBN1) or in a recent cross-anxiety disorders EWAS (TAOK1) after pre-processing and quality control (N = 378 vs. N = 295). Furthermore, BL DNA methylation at seven and three CpGs, respectively, was suggestively (p < 1E-5) associated with treatment response at POST (ABCA7, ADRA2C, LTBR, RPSAP52, SH3RF3, SLC47A2, ZNF251) and FU (ADGRD1, PRSS58, USP47). Finally, suggestive evidence for dynamic epigenome-wide DNA methylation changes along with CBT response emerged at four CpGs from BL to FU (ADIPOR2, EIF3B, OCA2, TMCC1). The identification of epigenetic biomarkers may eventually aid in developing environment-based preventive strategies aimed at increasing resilience by providing deeper molecular insights into the mechanisms underlying anxiety disorders. Defining epigenetic signatures as predictors or key mechanisms in exposure-based interventions could pave the way for more targeted and personalized treatments for anxiety disorders.
引用
- Domschke K, Schiele MA, Crespo Salvador Ó, et al. Epigenetic markers of disease risk and psychotherapy response in anxiety disorders - a longitudinal analysis of the DNA methylome. Mol Psychiatry. 2025. PMID: 40281224. doi:10.1038/s41380-025-03038-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。